Optiscan CEO Dr Camile Farah recently hosted an investor webinar providing an update on the coordinated progress across our clinical, regulatory, technology and partnership activities as we advance towards our next phase of development and commercialisation.

Key Highlights Include:

Progress Across Optiscan’s Device Portfolio
Updates on InVue®, InForm™ and InSpecta™, including the continued advancement of key clinical and regulatory activities across each platform.

Breast Cancer Study at Royal Melbourne Hospital
An overview of the study now underway using both InVue® and InForm™, and its role in supporting clinical validation efforts.

Groundwork for US-Based Clinical Activities
Preparatory work supporting Optiscan’s future clinical programs in the United States, a key market for the company’s long-term growth.

Technology Platform Development
Progress on telepathology, AI imaging initiatives, and next-generation probe and scanner designs that support Optiscan’s integrated platform strategy.

Strengthening Strategic Partnerships
Updates on collaborations including Australian Clinical Labs, Mayo Clinic and other international partners that are helping accelerate validation, deployment and future commercial pathways.

Financial Position
Following the recently completed $17.75m equity raise, Optiscan now has a long funding runway to support ongoing development and commercialisation activities.